nChroma Bio

nChroma Bio is a private, preclinical-stage biotech founded in 2020 and headquartered in Boston, MA, USA. The company is pioneering a disease-first approach to genetic medicine, integrating epigenetic and gene-editing cargoes with a modular delivery platform (LNPs for liver, eVLPs for extrahepatic tissues) to create durable, targeted therapies. Its pipeline includes a Phase 1/2 candidate for chronic HBV and earlier research programs in cardiometabolic and CNS diseases, positioning it to address significant unmet needs in both hepatic and non-liver indications.

Modular in vivo delivery platform combining tailored genetic cargoes (epigenetic/gene editors) with targeted delivery vehicles: Lipid Nanoparticles (LNPs) for liver and Engineered Virus-Like Particles (eVLPs/DLVR particles) for extrahepatic tissue delivery.

nChroma competes in the crowded genetic medicine field, facing competition from large biopharma and biotechs in HBV (e.g., Gilead, Janssen, Arbutus) and in developing extrahepatic delivery technologies (e.g., companies like Beam Therapeutics, Verve Therapeutics, and many startups). Its differentiation lies in its disease-first design and combined focus on epigenetic cargo with a modular, dual-delivery platform.